Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications

Pediatric Infectious Disease Journal

Volumn 30, Issue 12, 2011, Pages 1069-1074

  Crain, Marilyn J ^a   Williams, Paige L ^b   Griner, Ray ^b   Tassiopoulos, Katherine ^c   Read, Jennifer S ^d   Mofenson, Lynne M ^d   Rich, Kenneth C ^e  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

antiretroviral medication; HIV exposed infants; hyperlactatemia; point of care lactate

Indexed keywords

ABACAVIR; ATAZANAVIR; COCAINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LACTIC ACID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; OPIATE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CAPILLARY BLOOD; CHILD; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; EUROPEAN AMERICAN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POINT OF CARE TESTING; PRENATAL EXPOSURE; PRIORITY JOURNAL; RACE DIFFERENCE; SCREENING TEST; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; BLOOD CHEMICAL ANALYSIS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LACTIC ACID; MALE; MATERNAL-FETAL EXCHANGE; ODDS RATIO; POINT-OF-CARE SYSTEMS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 81855164872     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318234c886     Document Type: Article

References (39)

1. Huynh TK, Luttichau HR, Roge BT, et al. Natural history of hyperlactataemia in human immunodeficiency virus-1-infected patients during highly active antiretroviral therapy. Scand J Infect Dis. 2003;35:62-66. (Pubitemid 36336370)
2. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 2002;16:1341-1349. (Pubitemid 34722065)
3. Carr A. Lactic acidemia in infection with human immunodeficiency virus. Clin Infect Dis. 2003;36(suppl 2):S96-S100. (Pubitemid 36408118)
4. Lonergan JT, McComsey GA, Fisher RL, et al. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr. 2004;36:935-942. (Pubitemid 38944089)
5. Haugaard SB, Andersen O, Madsbad S, et al. Glucose production, oxidation and disposal correlate with plasma lactate levels in HIV-infected patients on HAART. J Infect. 2007;54:89-97. (Pubitemid 44932938)
6. Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS. 2007;21:2455-2464.
7. Montaner JS, Cote HC, Harris M, et al. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34(suppl 1):S85-S90. (Pubitemid 37158638)
8. Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J. 2003;22:782-789.
9. Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS. 2001;15:1074-1075. (Pubitemid 32476682)
10. Noguera A, Fortuny C, Sanchez E, et al. Hyperlactatemia in human immunodeficiency virus-uninfected children receiving antiretroviral treatment. Pediatr Infect Dis J. 2003;22:778-782. (Pubitemid 37153070)
11. Ekouevi DK, Toure R, Becquet R, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics. 2006;118: e1071-e1077. (Pubitemid 46393756)
12. Benhammou V, Tardieu M, Warszawski J, et al. Clinical mitochondrial dysfunction in uninfected children born to HIV-infected mothers following perinatal exposure to nucleoside analogues. Environ Mol Mutagen. 2007; 48:173-178. (Pubitemid 46536085)
13. Scalfaro P, Chesaux JJ, Buchwalder PA, et al. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med. 1998;24:247-250. (Pubitemid 28190817)
14. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999; 354:1084-1089. (Pubitemid 29452821)
15. Haas RH, Parikh S, Falk MJ, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics. 2007;120:1326-1333. (Pubitemid 350223685)
16. Goyal M, Pines JM, Drumheller BC, et al. Point-of-care testing at triage decreases time to lactate level in septic patients. J Emerg Med. 2010;38: 578-581.
17. Ridenour RV, Gada RP, Brost BC, et al. Comparison and validation of point of care lactate meters as a replacement for fetal pH measurement. Clin Biochem. 2008;41:1461-1465.
18. Saunders AC, Feldman HA, Correia CE, et al. Clinical evaluation of a portable lactate meter in type I glycogen storage disease. J Inherit Metab Dis. 2005;28:695-701. (Pubitemid 41349256)
19. Rivas P, Polo J, de Gorgolas M, et al. Drug points: fatal lactic acidosis associated with tenofovir. BMJ. 2003;327:711. (Pubitemid 37176751)
20. Kiragga AK, Ocama P, Reynolds SJ, et al. Validation of a portable hand-held lactate analyzer for determination of blood lactate in patients on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr. 2008;49: 564-566.
21. Perez EH, Dawood H, Chetty U, et al. Validation of the Accutrend lactate meter for hyperlactatemia screening during antiretroviral therapy in a resource-poor setting. Int J Infect Dis. 2008;12:553-556.
22. Ivers LC, Mukherjee JS. Point of care testing for antiretroviral therapyrelated lactic acidosis in resource-poor settings. AIDS. 2006;20:779-780. (Pubitemid 43884308)
23. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA. 1999;281:151-157. (Pubitemid 29045347)
24. Aldrovandi GM, Chu C, Shearer WT, et al. Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics. 2009;124:e1189-e1197.
25. Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion. 2004;4:763-777. (Pubitemid 39646821)
26. Dagan T, Sable C, Bray J, et al. Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? Mitochondrion. 2002;1:397-412. (Pubitemid 34461239)
27. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis. 2007;45:254-260. (Pubitemid 47041019)
28. Munnich A, Rotig A, Chretien D, et al. Clinical presentation of mitochondrial disorders in childhood. J Inherit Metab Dis. 1996;19:521-527. (Pubitemid 26302527)
29. Jansen TC, van Bommel J, Woodward R, et al. Association between blood lactate levels, Sequential Organ Failure Assessment subscores, and 28-day mortality during early and late intensive care unit stay: a retrospective observational study. Crit Care Med. 2009;37:2369-2374.
30. Koenig MK. Presentation and diagnosis of mitochondrial disorders in children. Pediatr Neurol. 2008;38:305-313. (Pubitemid 351503725)
31. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-1744. (Pubitemid 28454438)
32. Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis. 2000;13:5-11. (Pubitemid 30168547)
33. McComsey G, Lonergan JT. Mitochondrial dysfunction: patient monitoring and toxicity management. J Acquir Immune Defic Syndr. 2004;37(suppl 1): S30-S35. (Pubitemid 39166642)
34. Gomez-Duran A, Pacheu-Grau D, Lopez-Gallardo E, et al. Unmasking the causes of multifactorial disorders: OXPHOS differences between mitochondrial haplogroups. Hum Mol Genet. 2010;19:3343-3353.
35. Curran JE, Johnson MP, Dyer TD, et al. Genetic determinants of mitochondrial content. Hum Mol Genet. 2007;16:1504-1514. (Pubitemid 47055122)
36. Groener JB, Seybold U, Vollbrecht T, et al. Decrease in mitochondrial transmembrane potential in peripheral blood mononuclear cells of HIVuninfected subjects undergoing HIV postexposure prophylaxis. AIDS Res Hum Retroviruses. 2011;27:969-972.
37. Panos G, Kopterides P, Falagas ME. Hyperlactatemia due to nevirapine. Ann Intern Med. 2006;145:867-868. (Pubitemid 351650349)
38. Griner R, Williams P, Read J, et al; for the Pediatric HIV/AIDS Cohort Study. In utero and postnatal exposure to antiretrovirals among HIVexposed but uninfected children in the United States. AIDS Patient Care and STDS. 2011;25:385-394.
39. Nasi M, Guaraldi G, Orlando G, et al. Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy. Clin Infect Dis. 2008;47:962-968.